BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 34476650)

  • 21. Prevalence of germline pathogenic
    Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
    J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance.
    Abe T; Blackford AL; Tamura K; Ford M; McCormick P; Chuidian M; Almario JA; Borges M; Lennon AM; Shin EJ; Klein AP; Hruban RH; Canto MI; Goggins M
    J Clin Oncol; 2019 May; 37(13):1070-1080. PubMed ID: 30883245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice: A Review.
    Rainone M; Singh I; Salo-Mullen EE; Stadler ZK; O'Reilly EM
    JAMA Oncol; 2020 May; 6(5):764-771. PubMed ID: 32053139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).
    Harter P; Hauke J; Heitz F; Reuss A; Kommoss S; Marmé F; Heimbach A; Prieske K; Richters L; Burges A; Neidhardt G; de Gregorio N; El-Balat A; Hilpert F; Meier W; Kimmig R; Kast K; Sehouli J; Baumann K; Jackisch C; Park-Simon TW; Hanker L; Kröber S; Pfisterer J; Gevensleben H; Schnelzer A; Dietrich D; Neunhöffer T; Krockenberger M; Brucker SY; Nürnberg P; Thiele H; Altmüller J; Lamla J; Elser G; du Bois A; Hahnen E; Schmutzler R
    PLoS One; 2017; 12(10):e0186043. PubMed ID: 29053726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EUS-based Pancreatic Cancer Surveillance in
    Katona BW; Long JM; Ahmad NA; Attalla S; Bradbury AR; Carpenter EL; Clark DF; Constantino G; Das KK; Domchek SM; Dudzik C; Ebrahimzadeh J; Ginsberg GG; Heiman J; Kochman ML; Maxwell KN; McKenna DB; Powers J; Shah PD; Wangensteen KJ; Rustgi AK
    Cancer Prev Res (Phila); 2021 Nov; 14(11):1033-1040. PubMed ID: 34341011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and Spectrum of
    Foglietta J; Ludovini V; Bianconi F; Pistola L; Reda MS; Al-Refaie A; Tofanetti FR; Mosconi A; Minenza E; Anastasi P; Molica C; Stracci F; Roila F
    Genes (Basel); 2020 Aug; 11(8):. PubMed ID: 32806537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Familial pancreatic cancer with PALB2 and NBN pathogenic variants: a case report.
    Abe K; Ueki A; Urakawa Y; Kitago M; Yoshihama T; Nanki Y; Kitagawa Y; Aoki D; Kosaki K; Hirasawa A
    Hered Cancer Clin Pract; 2021 Jan; 19(1):5. PubMed ID: 33413558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Familial pancreatic carcinoma in Jews.
    Lynch HT; Deters CA; Lynch JF; Brand RE
    Fam Cancer; 2004; 3(3-4):233-40. PubMed ID: 15516847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pancreatic cancer screening in high-risk individuals with germline genetic mutations.
    DaVee T; Coronel E; Papafragkakis C; Thaiudom S; Lanke G; Chakinala RC; Nogueras González GM; Bhutani MS; Ross WA; Weston BR; Lee JH
    Gastrointest Endosc; 2018 Jun; 87(6):1443-1450. PubMed ID: 29309780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis.
    Sandoval RL; Leite ACR; Barbalho DM; Assad DX; Barroso R; Polidorio N; Dos Anjos CH; de Miranda AD; Ferreira ACSM; Fernandes GDS; Achatz MI
    PLoS One; 2021; 16(2):e0247363. PubMed ID: 33606809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer.
    Okawa Y; Iwasaki Y; Johnson TA; Ebata N; Inai C; Endo M; Maejima K; Sasagawa S; Fujita M; Matsuda K; Murakami Y; Nakamura T; Hirano S; Momozawa Y; Nakagawa H
    J Hepatol; 2023 Feb; 78(2):333-342. PubMed ID: 36243179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population.
    da Costa E Silva Carvalho S; Cury NM; Brotto DB; de Araujo LF; Rosa RCA; Texeira LA; Plaça JR; Marques AA; Peronni KC; Ruy PC; Molfetta GA; Moriguti JC; Carraro DM; Palmero EI; Ashton-Prolla P; de Faria Ferraz VE; Silva WA
    BMC Med Genomics; 2020 Feb; 13(1):21. PubMed ID: 32039725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer.
    Hu C; Hart SN; Polley EC; Gnanaolivu R; Shimelis H; Lee KY; Lilyquist J; Na J; Moore R; Antwi SO; Bamlet WR; Chaffee KG; DiCarlo J; Wu Z; Samara R; Kasi PM; McWilliams RR; Petersen GM; Couch FJ
    JAMA; 2018 Jun; 319(23):2401-2409. PubMed ID: 29922827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multi-gene panel study in hereditary breast and ovarian cancer in Colombia.
    Cock-Rada AM; Ossa CA; Garcia HI; Gomez LR
    Fam Cancer; 2018 Jan; 17(1):23-30. PubMed ID: 28528518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Glycated Hemoglobin With a Risk of Pancreatic Cancer in High-Risk Individuals Based on Genetic and Family History.
    Wu BU; Chen Q; Moon BH; Lustigova E; Nielsen EG; Alvarado M; Ahmed SA
    Clin Transl Gastroenterol; 2024 Jan; 15(1):e00650. PubMed ID: 37800692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
    Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
    Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer.
    Krepline AN; Geurts JL; Akinola I; Christians KK; Clarke CN; George B; Ritch PS; Khan AH; Hall WA; Erickson BA; Griffin MO; Evans DB; Tsai S
    HPB (Oxford); 2020 Dec; 22(12):1745-1752. PubMed ID: 32354656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic Variants in Patients With a Family History of Pancreatic Cancer: Impact of Multigene Panel Testing.
    Zhu H; Welinsky S; Soper ER; Brown KL; Abul-Husn NS; Lucas AL
    Pancreas; 2021 Apr; 50(4):602-606. PubMed ID: 33939675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review.
    Aslanian HR; Lee JH; Canto MI
    Gastroenterology; 2020 Jul; 159(1):358-362. PubMed ID: 32416142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer.
    Ryu JS; Lee HY; Cho EH; Yoon KA; Kim MK; Joo J; Lee ES; Kang HS; Lee S; Lee DO; Lim MC; Kong SY
    Cancer Sci; 2020 Oct; 111(10):3912-3925. PubMed ID: 32761968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.